Salix Presents New Rifaximin Phase IIb Data Demonstrating Significant And Sustained Improvement In Diarrhea-Associated Irritable Bowel Syndrome
May 22nd 2008Drug InformationIrritable-Bowel Syndrome
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced findings from two analyses of the Phase IIb clinical trial of rifaximin, its non-absorbed, gut-selective antibiotic for the treatment of patients with diarrhea-associated irritable bowel syndrome (d-IBS).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
